Semaglutide issues: what's real, what's manageable, and what needs attention

The biggest myth: all semaglutide side effects are equally serious

Walk through any online forum about Wegovy and you will find people convinced that nausea means the medicine is harming them, and others waving off symptoms that genuinely warrant a call to their prescriber. Neither instinct is quite right. The clinical reality is that semaglutide produces a spectrum of issues, most of which are dose-dependent and time-limited, and a much smaller number that need real attention.

Nausea is the single most commonly reported problem. In the STEP 1 trial (published in the New England Journal of Medicine) nausea affected a substantial proportion of participants but was overwhelmingly mild to moderate and declined as treatment continued. Vomiting, diarrhoea, constipation, burping and reflux follow a similar pattern: worst around a dose increase, easing as the body adjusts. Fatigue, headache and dizziness are also reported, particularly in the first few weeks.

None of that means you should dismiss these symptoms. If vomiting or diarrhoea is severe enough to stop you keeping fluids down, dehydration becomes a real risk, and that can affect your kidneys. The practical habit worth building: check your urine colour once a day during the first weeks at a new dose. Pale yellow is fine. Dark or very infrequent output is a prompt to increase fluids and, if it persists, contact your prescriber. Takes under a minute and catches early dehydration before it compounds.

The stomach issues people experience on Wegovy are covered in more depth separately, including practical approaches to timing meals and managing the rougher early weeks.

Semaglutide issues that go beyond the gut

Not every problem with semaglutide is digestive. A few deserve specific mention because they are either misattributed to something else or simply not talked about enough.

Gallbladder problems (including gallstones) occur at a higher rate with significant rapid weight loss generally, and GLP-1 medicines are no exception. Symptoms to recognise: pain in the upper right abdomen, sometimes radiating to the right shoulder, nausea, and potentially fever if infection is involved. This is not the garden-variety nausea of early treatment; it tends to be sharper, more localised and persistent. Get medical advice promptly.

Some people report changes to their menstrual cycle, particularly in the early months. Period changes on Wegovy are more common than many expect, often linked to shifts in body weight and hormonal signalling rather than a direct drug effect, but worth raising with your prescriber if they're significant or prolonged.

Sleep disruption is another issue that surfaces in patient reports. Sleep problems on Wegovy tend to be underreported and can have several contributing factors, including GI discomfort at night and the physiological changes that come with weight loss itself.

There is also emerging attention to eye health. A small body of evidence has raised questions about semaglutide and eye issues, particularly in people with pre-existing diabetic retinopathy. This remains an area of active monitoring; if you notice sudden visual changes, seek medical review promptly.

Finally, raised intracranial pressure (IIH) has been flagged in connection with weight loss medicines, including semaglutide. It is rare, but persistent or worsening headaches (especially with visual disturbance) are a reason to speak to a doctor rather than wait.

When semaglutide issues become urgent

The January 2026 MHRA Drug Safety Update on GLP-1 medicines put acute pancreatitis front and centre. It is an infrequent complication but potentially serious. The defining symptom is severe, persistent stomach pain that spreads toward the back, sometimes with vomiting. Ordinary nausea does not do this, it tends to come and go and sit more in the upper abdomen. Pain that radiates, that does not ease, that arrives suddenly and stays: stop taking the medicine and get urgent medical help. Do not wait for your next appointment.

Allergic reactions are rare but can be serious: swelling of the face, lips or throat, difficulty breathing, or a widespread rash appearing rapidly. These require emergency care.

Semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. It is not licensed for under-18s. Anyone with a history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2, or a personal history of pancreatitis needs a careful prescriber conversation before starting. These are not negotiable caveats, they exist because the medicine carries real contraindications that only a clinical assessment can properly weigh.

If anything about your experience on semaglutide concerns you, the wider Wegovy issues page covers the full range of reported problems alongside practical guidance on when to escalate. You can also report any suspected side effects directly to the MHRA through the Yellow Card scheme, linked above, your report contributes to the post-market safety picture for everyone using these medicines.

How clinical oversight changes the picture

One pattern our prescribers notice is that people who manage semaglutide issues least well are usually the ones navigating them alone. That is not a criticism; it is what happens when treatment is started without ongoing clinical support. Context matters enormously. Persistent nausea in week two of 0.25mg is almost certainly normal adjustment. The same nausea at week ten of the same dose, unchanged, is a reason to review whether the titration is working or something else is going on.

Access to treatment that includes proper aftercare (where a prescriber reads your case before every repeat, not just at sign-up) makes a practical difference to how these issues are caught and managed. A full overview of how Wegovy works and what the treatment involves is a useful starting point if you are weighing up options.

Cost is a real consideration for many people. The current Wegovy price landscape explains what private treatment typically costs in the UK and what to look for in a quote, because a headline price that does not include prescriber oversight, dose review and aftercare is not a like-for-like comparison.

If you have read this page and want to talk through your situation with a prescriber rather than continue searching, starting a free consultation with our clinical team is the practical next step.